Today: 20 May 2026
Browse Category

CSE:IAM 2 June 2025 - 4 August 2025

Inside the Struggle for Internet Access in Western Sahara: From Political Blackouts to Satellite Lifelines

Inside the Struggle for Internet Access in Western Sahara: From Political Blackouts to Satellite Lifelines

Western Sahara had about 398,000 internet users in January 2024, covering 67.1% of the population, up 19% from 2023. Median fixed broadband speed reached 19.9 Mbps, a 30% annual increase. Most users are urban; rural and nomadic areas remain largely offline. Connectivity relies on Moroccan operators, with Starlink and OneWeb set for future expansion pending regulatory approval.
4 August 2025
····
Global Tech Shake-Up: Massive Breakthroughs and Crises Rock the Industry (12–13 July 2025 Roundup)

Global Tech Shake-Up: Massive Breakthroughs and Crises Rock the Industry (12–13 July 2025 Roundup)

Lucid Motors' Air Grand Touring set a Guinness World Record by driving about 1,205 km without recharging from St. Moritz to Munich. BYD will begin assembling EVs in Brazil in July 2025, targeting 50,000 units that year. Intel revealed its Diamond Rapids Xeon CPU with 192 cores per socket. Samsung launched the Galaxy Z Fold 7 and Z Flip 7 in Seoul, adding new health sensors to the Galaxy Watch 8.
13 July 2025
············

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Go toTop